Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
2023 publication highlights
In 2023, cell researchers all over Europe, the USA, and Asia continued to show the versatility of HoloMonitor in their innovative research. In this blog, we present the researchers behind these studies and delve into the HoloMonitor publication highlights 2023 that unlock our cells’ secrets…
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share
PHI has appointed Pareto Securities as the Company’s liquidity provider.
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
Directed issue registered at the Companies Registration Office
PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.